Agile Therapeutics Inc (AGRX) Quote

AGRX: Shareholders of Agile Therapeutics, Inc. (AGRX) will receive $1.52/share in connection with the merger with Insud Pharma S.L

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

https://www.otcmarkets.com/stock/AGRX/news/Agile-Therapeutics-Inc-Announces-Definitive-Merger-Agreement-with-Insud-Pharma-SL?id=445020

Your welcome!

Thanks

CTB fees over 200% now...pressure is building for a huge rip.

CTB fees over 100% and float less than 10 mil. Strong bounce coming.

AGRX new 52 week lo

Looking tasty for a swing.

AGRX delisted from the Nasdaq to the OTC. Stock dropped 62% from .54 to .21 after hours.

https://otce.finra.org/otce/dailyList?viewType=Additions

AGRX new 52 week lo

Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution

AGRX new 52 week low

AGRX 10Q due March 13

AGRX 10Q due March 6

AGRX new 52 week low

AGRX new 52=week low

Ha!

AGRX new 52 week low

AGRX new 52 week low

AGRX new 52 week low

AGRX new 52 week low

AGRX new 52 week low

APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover

AGRX: WOW!! O.K., I can handle that!!

The float is limited to under 1 mil shares so if this goes $10 I wouldn't be surprised

AGRX: Heck, I had to launch my "DDAmanda-Time-Machine" (see ME, below) to recall MY post way back then, Dude!! (But, THANKS for the huge heads-up, Boss!!!)

Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™

Partnership Expected to Augment Future Growth in the Retail Channel, the Company’s Most-Profitable Channel

Expanding Commercial Reach through Strategic Partnerships Continues to Drive Company’s Belief in Achieving 2023 Net Revenue in the Range of $25-$30 Million

PRINCETON, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a women's healthcare company, today announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx, to expand patient access and streamline fulfillment for Twirla (levonorgestrel ethinyl estradiol) transdermal system. VitaCare is a technology and services platform that helps patients navigate key access barriers for branded medications.

“The agreement with vitaCare aligns with our strategy to utilize partnerships to efficiently grow Twirla while continuing to responsibly manage our operating expenses,” said Agile Therapeutics’ Chief Commercial Officer Amy Welsh.

“The goal for the vitaCare partnership is to strengthen Twirla’s already meaningful momentum in our most profitable channel – the retail channel. We believe the partnership with vitaCare will create more opportunity to reach new Twirla patients for whom access has been a barrier, while helping existing Twirla patients stay on therapy. Our on-going plan is to expand our commercial reach, which we expect will contribute to reaching our key 2023 financial goals of generating positive cash flow and delivering net revenue in the range of $25-$30 million.”

Agile continues to grow Twirla’s presence on telemedicine platforms, including Twentyeight Health, in addition to existing partners like Pandia Health and Nurx as more women choose telemedicine for their contraceptive needs. Twentyeight Health is a telehealth company providing affordable access and convenience for reproductive and sexual health and recently acquired the platform assets for SimpleHealth. The Company believes that the Twentyeight Health platform will provide an opportunity for more patients to learn about and access Twirla.

Premarket craziness today :)

Bounce coming

Louis Rossman with 122k subscribers on YouTube that covers technology repairs (i know unrelated)... while talking left this stock up on his screen for a good bit while talking.

That's a lot of eyes... it's a sign to buy this for a quick run in my opinion.

What a shit show operation.

The lawyer's base salary is 3 times their 6 month profit with an almost automatic 45% "bonus" for a company that LOSES MONEY as a business.

Time for the board to be replaced with active brain cells in their directors.

$AGRX .47 buy =)

agrx 52 week low

They upgrade guidance and the stock goes down? Wtf is up with this thang?????

.72 close breakout watch tomorrow

Offering closed! Sweet!

An offering always PROPOSED/POSITIONED to grown the business. Time will tell....

The only thing we can hope for is to cancel the offering (seen this on multiple bios this week). Because without that, a reverse is coming right after the offering is closed. Get ready to pull that trigger!

Thought it might be a way to grow business but wasnt sure. Thanks

Money buys ships and grows the business.

SHELF OFFERING is that a good thing or bad thing as we see it.

Back in at $1.75, looking to flip again today. Anything under $1.80 looks great!

if you liked it at 1.75 youre lovin it at .66

Time to buy

Yeah...priced at .90 and it's in the .60's? Jesus...

Shelf offering : SEC FORM S-1 >

Well isn't this just awesome

Back in at $1.75, looking to flip again today. Anything under $1.80 looks great!

Buy this dip! Easy money flip later today

Agile Therapeutics Stock Surges 70%
By RTTNews Staff Writer ? | Published: 6/28/2022 10:57 AM ET
Shares of Agile Therapeutics, Inc. (AGRX) are surging over 70% on Tuesday morning despite no stock-related new release from the company.

AGRX is currently trading at $2.1608, up $0.8908 or 70.1417%, on the Nasdaq. The stock opened its trading at $1.67 after closing Monday's trading at $1.27.

Agile Therapeutics, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Biotech Stocks Facing FDA Decision In June 2022
Biotech Stocks Facing FDA Decision In June 2022

Biotech Stocks Facing FDA Decision In March 2022
Biotech Stocks Facing FDA Decision In March 2022

Biotech Stocks Facing FDA Decision In February 2022 non small cell lung cancer chemotherapy
Biotech Stocks Facing FDA Decision In February 2022

Previous StoryNext Story


Latest Updates on COVID-19
18K New Covid Cases, 144 Deaths In US
184K New Covid Cases, 860 Deaths In U.S.
50K New Covid Cases, 80 Deaths In U.S.
Sanofi-GSK Reports Positive Data From COVID-19 Beta-containing Vaccine Trial
FDA Advisers Recommend Pfizer, Moderna COVID-19 Vaccines For Kids As Young As 6 Months
Read MoreCOVID-19: Drugs in Development
RELATED NEWS
Agile Therapeutics Stock Surges 70%

Follow RTT
FacebookTwitterInstagramRSS
Editor's Pick Most Read Most Emailed
FDA Proposes Rule To Advance Consumer Access To OTC Drugs
US To Get 21 Mln Bottles Of Bellamy's Organic Infant Formula From Australia
Flight Cancellations, Delays On The Rise In US
FSIS Warns Against Ineligible Siluriformes Products Imported From Korea
Panera At Home Southwest Corn Chowder Recalled
MTD Products Recalls Walk-Behind Self-Propelled Lawn Mowers
Nike To Fully Exit Russia As Ukraine Invasion Continues
FDA Action Plan To Speed Up Drug Development For Rare Neurodegenerative Diseases
Loctek Recalls Fleximouts Overhead Garage Storage Racks
US To Import Millions Of Infant Formula Bottles From UK, Australia, Mexico
CVS Magnesium Citrate Saline Laxative Oral Solution Lemon Flavor Recalled
FDA Probes Death Of Infant Who Consumed Abbott Infant Formula



Copyright © 2022 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.
About Us | Contact Us | Privacy | Sitemap
Share to Facebook
Share to Twitter
Share to Pinterest
Share to Email

These biotechs can really run when they have good news. Biotechs have been really beaten down lately...